![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, May 29, 2021 7:48:54 PM
With hundreds of companies forming IBD's biotechnology industry group, investors naturally seek big profits in the ever-dynamic space. And why not? Huge breakouts and five-, tenfold moves by the likes of Amgen (AMGN), Biogen (BIIB), Celgene (acquired by Bristol Myers Squibb (BMY)), Genentech (acquired by Roche (RHBBY)) and Regeneron Pharmaceuticals (REGN) have become Wall Street lore.
But are there some practical tips to help you consistently make money in the stock market — especially in this volatile field of industry? Consider three.
Tip No. 1:
Try a scattershot approach. Buy a highly liquid exchange traded fund such as the SPDR S&P Biotech (XBI) ETF. It ranks among leading ETFs tracked by IBD. Want more juice? ProShares Ultra Nasdaq Biotechnology (BIB) seeks to deliver twice the return of the Nasdaq Biotechnology Index. One big problem: It can crush your portfolio during steep market downturns. So, be disciplined with timing. Buy only when you see a follow-through day after a bear market. The Big Picture can help in this regard.
Tip No. 2:
The best companies deliver the most shareholder value by creating a product that radically changes the face of medicine. Amgen revolutionized patient care in chemotherapy. Celgene addressed tough diseases with its own discoveries. In 2021, we're seeing the fruits of messenger RNA technology leading to the rapid development of Covid-19 vaccines.
You don't have to grab shares in huge winners by trying to pick the bottom. Instead, look for companies that form good bases that signal heavy institutional accumulation.
Tip No. 3? Marc Lichtenfeld, an expert in biotech and income stocks, notes that a lot of Wall Street money moves into companies that issue positive Phase 2 clinical trial data. Such news can spark big breakouts and solid price runs over the span of months or a few years. But few companies succeed as well when they get to Phase 3 of a drug trial.
https://www.investors.com/how-to-invest/investors-corner/how-to-trade-biotech-stocks-three-tips-help-make-more-profits/
Recent SBFM News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:05:31 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 03/05/2024 09:37:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:05:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/23/2024 09:03:01 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/21/2024 09:28:39 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 02/21/2024 01:24:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 10:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 04:39:32 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:53:03 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/14/2024 04:18:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/13/2024 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:05:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 02:04:50 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/09/2024 10:17:56 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/01/2024 09:17:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 05:38:24 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/08/2024 01:10:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:59:51 PM
- Sunshine Biopharma Moves Principal Office to New York City • GlobeNewswire Inc. • 12/04/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:00:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 04:18:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/20/2023 05:06:33 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/19/2023 04:10:36 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM